Standard of care
Standard of care
Coverage limit
This map is not available yet.
This file does not state a treatment pathway by setting or line. The notes below are approval facts the seed sources state. They are not a line of therapy.
Standard of care map coming. The obesity seed does not state a treatment pathway by setting or line. The notes below repeat approval facts that the seed sources state.
NOT INVESTMENT ADVICE. This is a general evidence review, not individualized medical advice. A line is shown only when the cited review or a trial record in this file states it.
Approval notes
- Semaglutide (Wegovy)The seed source states that Wegovy (semaglutide) injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and that Wegovy tablets are indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity.src-wegovy-label
- Tirzepatide (Zepbound)The seed source states that Zepbound (tirzepatide) is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight related comorbid condition.src-zepbound-label
- Orforglipron (Foundayo)The seed source states that the Foundayo (orforglipron) application provides for use, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight related comorbid condition, and that it is approved.src-foundayo-letter
- Liraglutide (Saxenda)The seed source states that the safety and effectiveness of Saxenda (liraglutide) as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management have been established in pediatric patients aged 12 years and older with body weight above 60 kg and an initial BMI corresponding to 30 kg/m2 or greater.src-label-liraglutide
- Orlistat (Xenical)The seed records orlistat as approved and links this label. The stored quote does not state a weight management indication or a treatment line.src-label-orlistat